GSK's Tafinlar named as FDA breakthrough therapy for lung cancer

LONDON Mon Jan 13, 2014 10:42am EST

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai July 12, 2013. REUTERS/Aly Song

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai July 12, 2013.

Credit: Reuters/Aly Song

Related Topics

LONDON (Reuters) - British pharmaceutical company GlaxoSmithKline said its Tafinlar cancer treatment had been given FDA breakthrough therapy designation for lung cancer, meaning the drug will be fast-tracked within the U.S. regulatory system.

GSK said that Tafinlar, also known as dabrafenib, was designated an FDA breakthrough therapy on Monday following interim results from an ongoing Phase II study.

Tafinlar is already approved for melanoma, the deadliest form of skin cancer.

(Reporting by Sarah Young, Editing by Paul Sandle)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
maewh wrote:
For people interested in natural methods to possibly heal cancer you may like to research Salvestrols. Professor Burke of Aberdeen University discovered that all cancer cells have CYP1B1 enzyme. Professor Potter at De Montfort University discovered natural compounds found in fruits vegetables and herbs that transform CYP1B1 enzyme into anti-cancer agents. He named them Salvestrols. Burke and Potter got together with Anthony Daniels and created Salvestrol supplements. Peer reviewed case studies demonstrate that 11 of 11 people with all types of cancers were cured with Salvestrol pills. Google ‘salvestrol case studies’ and google ‘Salvestrol Platinum’ pills.

Jan 14, 2014 2:56pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.